Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
A new treatment option gets FDA approval for adults with advanced Parkinson’s disease
The US Food and Drug Administration has approved VYALEV, a groundbreaking therapy developed by AbbVie to treat adults with advanced Parkinson's disease. This novel treatment is the first of its kind,
FDA approves AbbVie’s VYALEV for advanced Parkinson’s treatment
The US Food and Drug Administration (FDA) has approved AbbVie's VYALEV (foscarbidopa and foslevodopa) to treat motor fluctuations in adults with advanced Parkinson's disease (PD). The chronic neurological disorder is marked by symptoms such as tremors and muscle rigidity,
AbbVie Secures FDA Approval for Parkinson's Disease Drug Vyalev
AbbVie ABBV announced that the FDA has approved its subcutaneous administered drug ABBV-951 to treat motor fluctuations in adult patients with advanced Parkinson's disease (PD). The drug will be marketed under the trade name Vyalev.
Injectable drug to ease advanced Parkinson's disease symptoms approved by FDA
The FDA on Thursday approved an injectable drug that eased Parkinson's disease symptoms and improved motor fluctuations in study participants.
FDA Approves AbbVie's VYALEV as First 24-Hour Levodopa Infusion for Advanced Parkinson's
The first levodopa-based treatment for motor fluctuations in people with advanced Parkinson's disease, VYALEVa subcutaneous 24-hour continuous infusion of foscarbidopa and foslevodopais now authorized by the U.S. Food and Drug Administration, AbbVie ( ABBV, Financials) said Thursday.
AbbVie’s continuous Parkinson’s disease therapy Vyalev approved by FDA
AbbVie’s Parkinson’s disease (PD) therapy has been approved by the US Food and Drug Administration (FDA) to treat motor fluctuations in adults with advanced stages of the chronic movement disorder. Vyalev is a solution of foscarbidopa and foslevodopa,
FDA finally approves Vyalev for Parkinson’s disease
After a couple of negative decisions, the US Food and Drug Administration (FDA) has approved Vyalev (foscarbidopa and foslevodopa), from AbbVie, as the first and only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of motor fluctuations in adults with advanced Parkinson's disease (PD).
AbbVie wins FDA nod for infusion treatment for advanced Parkinson’s disease
Vyalev is the first subcutaneous 24-hour continuous infusion of levodopa-based therapy for advanced Parkinson’s disease.
AbbVie’s Vyalev approved by FDA in advanced Parkinson’s disease
AbbVie announced that the FDA has approved Vyalev as the first and only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of motor fluctuations in adults with advanced Parkinson’s disease.
FiercePharma
5d
3rd time's the charm: AbbVie scores FDA nod for continuous Parkinson's disease therapy Vyalev
AbbVie made history in 2015 with its Parkinson’s disease infusion pump therapy Duopa, kicking off a trend of delivery system ...
pharmaphorum
4d
AbbVie gets continuous Parkinson's drug over the line in US
AbbVie has finally claimed FDA approval for its advanced Parkinson's disease therapy Vyalev, 18 months after the US regulator ...
Crain's Chicago Business
5d
New AbbVie Parkinson’s drug finally gets green light to hit U.S. market
After two previous failed attempts with the FDA, AbbVie now has one more offering in its lineup — a critical step as it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
Arrested in trafficking case
Sued by Murdoch’s firms
Crew ID’d in WA jet crash
1st trans lawyer at SCOTUS
Arizona official pleads guilty
Copyright infringement suit
Splits with NY magazine
Target to cut prices
Reveals 2025 tax brackets
To headline 2 Harris rallies
Washington state shooting
Meteorite aided early life?
Overseas ballot suits denied
China holds live-fire drills
Fuel pump concern recall
Tests facial recognition tech
Extends student loan pause
FTC bans fake reviews
$400M aid package for UKR
Probing leak of US intel
Right whale population rises
Raises US growth forecast
US data protection move
Infant mortality increased
PA political threat case
Peru ex-president sentenced
SK mulls arms for Ukraine
Blinken arrives in Israel
Recalled over listeria risk
Same-day pharmacy delivery
Related topics
AbbVie
Food and Drug Administration
levodopa
Feedback